Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 391

1.

Syncope in a Child with Pulmonary Hypertension and Positive Gene Tests for Hereditary Hemorrhagic Telangiectasia and Long QT Syndrome.

Das BB, Chan KC.

Cardiovasc Hematol Agents Med Chem. 2019 Oct 27. doi: 10.2174/1871525717666191028102503. [Epub ahead of print]

PMID:
31657683
2.

Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study).

Pan Z, Marra AM, Benjamin N, Eichstaedt CA, Blank N, Bossone E, Cittadini A, Coghlan G, Denton CP, Distler O, Egenlauf B, Fischer C, Harutyunova S, Xanthouli P, Lorenz HM, Grünig E.

Arthritis Res Ther. 2019 Oct 26;21(1):217. doi: 10.1186/s13075-019-1981-0.

3.

Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: Results from the AMBITION trial.

McLaughlin VV, Vachiery JL, Oudiz RJ, Rosenkranz S, Galiè N, Barberà JA, Frost AE, Ghofrani HA, Peacock AJ, Simonneau G, Rubin LJ, Blair C, Langley J, Hoeper MM; AMBITION Study Group.

J Heart Lung Transplant. 2019 Sep 17. pii: S1053-2498(19)31685-7. doi: 10.1016/j.healun.2019.09.010. [Epub ahead of print]

PMID:
31648845
4.

Endothelin Receptor Antagonists.

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.
2017 Sep 30.

5.

Ambrisentan.

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.
2017 Sep 30.

6.

Pharmacotherapy for pulmonary arterial hypertension.

Parikh V, Bhardwaj A, Nair A.

J Thorac Dis. 2019 Sep;11(Suppl 14):S1767-S1781. doi: 10.21037/jtd.2019.09.14. Review.

7.

Long-Term Response to Vasoactive Treatment in a Case of Kyphoscoliosis-Associated Pulmonary Hypertension.

Tellermann J, Sablinskis M, Machado PRR, Sablinskis K, Skride A.

Am J Case Rep. 2019 Oct 13;20:1505-1508. doi: 10.12659/AJCR.917154.

8.

Risk Reduction and Right Heart Reverse Remodeling by Upfront Triple Combination Therapy in Pulmonary Arterial Hypertension.

D'Alto M, Badagliacca R, Argiento P, Romeo E, Farro A, Papa S, Sarubbi B, Russo MG, Vizza CD, Golino P, Naeije R.

Chest. 2019 Sep 26. pii: S0012-3692(19)33935-2. doi: 10.1016/j.chest.2019.09.009. [Epub ahead of print]

PMID:
31563498
9.

A Retrospective Analysis of Adherence to Risk Evaluation and Mitigation Strategies Requirements for Pulmonary Arterial Hypertension Drugs.

Prokes M, Root A.

Hosp Pharm. 2019 Oct;54(5):309-313. doi: 10.1177/0018578718791509. Epub 2018 Aug 1.

PMID:
31555006
10.

Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension.

White RJ, Vonk-Noordegraaf A, Rosenkranz S, Oudiz RJ, McLaughlin VV, Hoeper MM, Grünig E, Ghofrani HA, Chakinala MM, Barberà JA, Blair C, Langley J, Frost AE.

Respir Res. 2019 Sep 12;20(1):208. doi: 10.1186/s12931-019-1180-1.

11.

Implication of Differential Surface Anisotropy on Biopharmaceutical Performance of Polymorphic Forms of Ambrisentan.

Haneef J, Chadha R.

J Pharm Sci. 2019 Aug 23. pii: S0022-3549(19)30517-9. doi: 10.1016/j.xphs.2019.08.016. [Epub ahead of print]

PMID:
31449817
12.

Combination Therapy in Pulmonary Arterial Hypertension: Gleaning a Practical Approach from the Randomized Trials.

Booth DC.

Int J Angiol. 2019 Jun;28(2):93-99. doi: 10.1055/s-0039-1691791. Epub 2019 Jul 12.

PMID:
31384106
13.

Combination therapy improves vascular volume in female rats with pulmonary hypertension.

Lachant DJ, Meoli DF, Haight D, Staicu S, Akers S, Glickman S, Ambrosini R, Champion HC, White RJ.

Am J Physiol Lung Cell Mol Physiol. 2019 Oct 1;317(4):L445-L455. doi: 10.1152/ajplung.00450.2018. Epub 2019 Jul 19.

PMID:
31322432
14.

A network meta-analysis for safety of endothelin receptor antagonists in pulmonary arterial hypertension.

Zhang YJ, Wang N, Gu ZC, Wei AH, Cheng AN, Fang SS, Du HL, Wang LZ, Zhang GQ.

Cardiovasc Diagn Ther. 2019 Jun;9(3):239-249. doi: 10.21037/cdt.2019.03.02.

15.

Small Molecule IL-36γ Antagonist as a Novel Therapeutic Approach for Plaque Psoriasis.

Todorović V, Su Z, Putman CB, Kakavas SJ, Salte KM, McDonald HA, Wetter JB, Paulsboe SE, Sun Q, Gerstein CE, Medina L, Sielaff B, Sadhukhan R, Stockmann H, Richardson PL, Qiu W, Argiriadi MA, Henry RF, Herold JM, Shotwell JB, McGaraughty SP, Honore P, Gopalakrishnan SM, Sun CC, Scott VE.

Sci Rep. 2019 Jun 24;9(1):9089. doi: 10.1038/s41598-019-45626-w.

16.

Pharmacokinetics of ambrisentan in a patient with Pulmonary Arterial Hypertension and a total gastrectomy.

Abston E, Farber HW.

Pulm Pharmacol Ther. 2019 Aug;57:101813. doi: 10.1016/j.pupt.2019.101813. Epub 2019 Jun 12.

PMID:
31199984
17.
18.

Liver safety evaluation of endothelin receptor antagonists using HepatoPac® : A single model impact assessment on hepatocellular health, function and bile acid disposition.

Aleo MD, Ukairo O, Moore A, Irrechukwu O, Potter DM, Schneider RP.

J Appl Toxicol. 2019 Aug;39(8):1192-1207. doi: 10.1002/jat.3805. Epub 2019 May 27.

PMID:
31134659
19.

What is the position of pulmonary arterial hypertension-specific drug therapy in patients with Eisenmenger syndrome: A systematic review and meta-analysis.

Li Q, Kuang HY, Wu YH, Lu TW, Yi QJ.

Medicine (Baltimore). 2019 May;98(20):e15632. doi: 10.1097/MD.0000000000015632.

20.

Pulmonary arterial hypertension in Russia: six-year observation analysis of the National Registry.

Chazova IE, Arkhipova OA, Martynyuk TV.

Ter Arkh. 2019 Mar 10;91(1):24-31. doi: 10.26442/00403660.2019.01.000024.

PMID:
31090367

Supplemental Content

Loading ...
Support Center